Cell Stem Cell Impact Factor

The first signal is dominance within the field. A rank of 1/32 means Cell Stem Cell is not just prestigious. It is the category leader by JCR position.

The second signal is durability. The five-year JIF of 21.8 beats the current JIF, which suggests the journal's strongest papers continue to matter after the initial attention wave.

The third signal is normalized strength. The JCI of 4.12 is very strong. That matters because stem cell papers can draw from developmental biology, regenerative medicine, genomics, cancer, and translational medicine, all with different citation patterns.

The fourth signal is cleanliness. The JIF without self-cites is 19.8, essentially the same as the headline JIF. That tells you the metric is being supported broadly across the field.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 12.46 in 2023 to 12.67 in 2024, but still below earlier highs. The broader pattern is a consistently elite journal with some oscillation, not a venue dependent on one unusual cycle.

That fits the Cell Press identity. The journal continues to publish across the core spectrum of stem cell biology, and the metrics still reflect broad field attention.

The most common mistake is to see 20.4 and assume a very strong technical stem cell paper is enough.

That misses the real screen. The official ScienceDirect insights page still frames Cell Stem Cell as a broad-spectrum journal across the full stem cell field. That breadth actually raises the bar:

• the result has to matter beyond one narrow model or platform
• the significance case has to be obvious to a field-wide stem cell readership
• the paper usually needs conceptual consequence, not only technical competence

The impact factor says the journal is elite. It does not say that every strong stem cell paper is a Cell Stem Cell paper.

In our pre-submission review work with manuscripts targeting Cell Stem Cell, three patterns generate the most consistent desk-rejection outcomes.

The study is technically excellent but conceptually too incremental. We often see papers that advance one method, one differentiation system, or one platform without enough broader field consequence.

The significance stays trapped inside one model system. The work can be strong and still feel too narrow if the lesson does not travel.

The paper is important, but the stronger owner is another top journal. Some papers are more clearly developmental biology, cancer, or general cell biology than stem cell field leaders.

If that sounds familiar, a Cell Stem Cell submission readiness review is usually more useful than another pass on style.

The official ScienceDirect insights page currently adds several useful non-JCR signals:

• CiteScore 32.9
• Impact Factor 20.4
• Submission to first decision: 4 days
• Submission to decision after review: 33 days

That matters because it shows the journal's actual operating model. Cell Stem Cell combines field-leading status with very fast editorial triage.

There is also a public presubmission inquiry channel, which is a good signal in itself. Cell Press is effectively telling authors that fit is hard enough here that early editorial steering can be worthwhile.

The impact factor does not tell you whether the paper has enough field-wide consequence, whether the conceptual gain is large enough, or whether another top journal is the cleaner owner.

That is the central trap. The number is real, but fit still decides most outcomes.